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The short arm of chromosome 8 is one of the most frequently altered in breast cancer. Chromosome 8p abnormalities have been associated with the development and/or progression of breast cancer and 8p22 deletions have been associated with more aggressive phenotypes and poorer survival ([Yokota *et al*, 1999](#bib21){ref-type="other"}; [Utada *et al*, 2000](#bib18){ref-type="other"}). Amplification of the region 8p12, that contains the neuregulin (NRG-1, also denominated heregulin) gene, is detected in about 12% of breast tumours ([Adélaïde *et al*, 1994](#bib1){ref-type="other"}, [1998](#bib2){ref-type="other"}; [Lee and Wood, 1993](#bib9){ref-type="other"}) and breakpoints in bands 8p11-p21 have been reported in breast cancer ([Morris *et al*, 1997](#bib13){ref-type="other"}; [Courtay-Cahen *et al*, 2000](#bib6){ref-type="other"}). The NRG-1 gene encodes, by alternative splicing or by initiation of gene transcripts at different sites, a family of more than 15 membrane bound or secreted proteins most of which contain an extracellular epidermal growth factor (EGF)-like domain ([Peles and Yarden, 1993](#bib14){ref-type="other"}). These proteins act as ligands for the HER family of receptor tyrosine kinases and play an important role in cell growth and differentiation, morphogenesis and apoptosis ([Burden and Yarden, 1997](#bib4){ref-type="other"}). Although NRG-1 was isolated during the search for a HER-2 ligand ([Holmes *et al*, 1992](#bib7){ref-type="other"}), isoforms of NRG-1 bind to cells that express HER-3 or HER-4 receptors alone, heterodimers of HER-2 with either HER-3 or HER-4 but not to cells that express monomers of HER-2 ([Burden and Yarden, 1997](#bib4){ref-type="other"}).

Much interest in the neuregulins is based on the fact that the receptors for these ligands, the HER family of proteins, are amplified or over-expressed in breast cancer. HER-2 (also known as neu and erbB2) gene amplification and/or over-expression are found in approximately one-third of breast tumours and have been associated with a poor prognosis ([Lupu *et al*, 1996](#bib12){ref-type="other"}). NRG-1 induces an aggressive/invasive transformed morphology in cultured mammary epithelial cells that express HER-2 ([Lupu *et al*, 1996](#bib12){ref-type="other"}) and can stimulate the growth of breast cancer cells that express low levels of the HER-2 receptor ([Schaefer *et al*, 1997](#bib16){ref-type="other"}). Moreover, NRG-1 synthesised by the mesenchyme has been implicated in mammary development ([Carraway *et al*, 1997](#bib5){ref-type="other"}), and it has been demonstrated that NRG-1 induces proliferation or differentiation of various mammary tumour cell lines, initiates programmed cell death and induces cell differentiation in breast tumours ([Ram *et al*, 1995](#bib15){ref-type="other"}; [Weinstein *et al*, 1998](#bib20){ref-type="other"}; [Le *et al*, 2000](#bib8){ref-type="other"}). Recently, it has been identified in MDA-MB-175, a breast carcinoma cell line that shows elevated levels of HER-2 ([Lewis *et al*, 1993](#bib10){ref-type="other"}), a translocation between chromosomes 8p12-21 and 11q13 that leads to the fusion of NRG-1 and DOC4 genes ([Schaefer *et al*, 1997](#bib16){ref-type="other"}; [Liu *et al*, 1999](#bib11){ref-type="other"}; [Wang *et al*, 1999](#bib19){ref-type="other"}; [Adélaïde *et al*, 2000](#bib3){ref-type="other"}). This translocation generates a new chimeric transcript that codes for a new isoform of the neuregulin family, denominated γ-heregulin (γ-HRG), that acts as an autocrine growth factor in the breast cancer cell line MDA-MB-175 ([Schaefer *et al*, 1997](#bib16){ref-type="other"}).

In an attempt to define the incidence of this translocation in Spanish women with breast cancer we have studied this abnormality in a series of 141 breast carcinoma samples collected at the University Hospital of Salamanca. All tumour specimens were frozen immediately after removal and stored at −80°C before processing. DNA was extracted as described ([Sánchez *et al*, 1995](#bib17){ref-type="other"}). The status of γ-HRG gene was assessed by Southern blot analysis. Genomic DNA was digested with the restriction endonuclease *Eco*RI and electrophoresed on 0.8% agarose gels. DNA was blotted and hybridised with a 538 bp *Sac*II-*Xho*I fragment (nt 209--747 from sequence M94165) that spans the putative breakpoint site in chromosome 8p12.

Southern blot analysis of 141 primary breast carcinomas and the MCF-7 breast cancer cell line did not reveal any abnormal fragment. Our results show that the t(8;11)(p12;q13) translocation is not present in a large series of Spanish women with breast cancer and confirm previous reports that suggest that this translocation is a particularity of the MDA-MB-175 cell line and not a recurrent event ([Wang *et al*, 1999](#bib19){ref-type="other"}; [Adélaïde *et al*, 2000](#bib3){ref-type="other"}) indicating that γ-heregulin is not relevant in the development of breast cancer.
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